A randomized, double-blind, placebo-controlled, 2-period, multicenter, crossover outpatient study evaluating the efficacy and safety of Zolmitriptan Nasal pray (ZNS) for the acute treatment of migraine headaches in pediatric patients.

Trial Profile

A randomized, double-blind, placebo-controlled, 2-period, multicenter, crossover outpatient study evaluating the efficacy and safety of Zolmitriptan Nasal pray (ZNS) for the acute treatment of migraine headaches in pediatric patients.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 New trial record
    • 11 Jun 2017 Enrollment is planned to begin in late 2017 with results expected in 2019. The study will enroll approximately 426 subjects to randomize and treat 288.
    • 11 Jun 2017 Trial design presented at the 59th Annual Scientific Meeting of the American Headache Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top